Zealand Pharma Reports Transformative Year with Strong R&D Focus

Zealand Pharma A/S ( (ZLDPF) ) has released its Q4 earnings. Here is a breakdown of the information Zealand Pharma A/S presented to its investors.

Zealand Pharma A/S is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines, with a focus on therapeutic areas such as obesity, rare diseases, and chronic inflammation. In its 2024 annual report, Zealand Pharma highlighted a transformative year marked by significant advancements in its clinical-stage obesity portfolio, successful capital raises, and preparations for future growth. Key financial highlights include a substantial increase in cash and marketable securities due to two significant equity offerings, although the company recorded a net loss for the year. The report details promising results from trials of their obesity drugs, particularly petrelintide and dapiglutide, and the progression of their partnership with Boehringer Ingelheim on survodutide. Looking forward, Zealand Pharma aims to advance its mid- to late-stage obesity programs and continue its research into rare diseases and inflammation treatments, supported by a robust financial position that allows for ongoing investment in R&D.